Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-01

AUTHORS

Keiko Nakayama, Yoichi Kuwabara, Masao Daimon, Satoshi Shindo, Miwa Fujita, Hiroya Narumi, Hiroshi Mizuma, Issei Komuro

ABSTRACT

Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21−28) More... »

PAGES

21-28

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1291/hypres.31.21

DOI

http://dx.doi.org/10.1291/hypres.31.21

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010763509

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18360014


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "3-Iodobenzylguanidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amlodipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endpoint Determination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Informed Consent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radionuclide Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sample Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ultrasonography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valsartan", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakayama", 
        "givenName": "Keiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuwabara", 
        "givenName": "Yoichi", 
        "id": "sg:person.0752532133.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daimon", 
        "givenName": "Masao", 
        "id": "sg:person.01312065070.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312065070.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shindo", 
        "givenName": "Satoshi", 
        "id": "sg:person.01066760533.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujita", 
        "givenName": "Miwa", 
        "id": "sg:person.01135073733.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narumi", 
        "givenName": "Hiroya", 
        "id": "sg:person.01203207133.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuma", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01251322333.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1291/hypres.28.865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050983237", 
          "https://doi.org/10.1291/hypres.28.865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-199447060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034980850", 
          "https://doi.org/10.2165/00003495-199447060-00005"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01", 
    "datePublishedReg": "2008-01-01", 
    "description": "Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21\u221228)", 
    "genre": "article", 
    "id": "sg:pub.10.1291/hypres.31.21", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Japanese Society of Hypertension", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "cardiovascular events", 
      "blood pressure", 
      "randomized trials", 
      "angiotensin II type 1 receptor blocker", 
      "type 1 receptor blocker", 
      "hypertension-related morbidity", 
      "open-label trial", 
      "cardiovascular disease events", 
      "proportion of patients", 
      "calcium channel blockers", 
      "antihypertensive therapy", 
      "amlodipine group", 
      "receptor blockers", 
      "essential hypertensives", 
      "optimal therapy", 
      "clinical outcomes", 
      "Japanese patients", 
      "urine studies", 
      "channel blockers", 
      "disease events", 
      "patients", 
      "trials", 
      "treatment effects", 
      "blockers", 
      "therapy", 
      "background factors", 
      "baseline", 
      "random assignment", 
      "target level", 
      "laboratory tests", 
      "group", 
      "hypertensives", 
      "data entry", 
      "hyperlipidemia", 
      "morbidity", 
      "echocardiography", 
      "diabetes", 
      "valsartan", 
      "mortality", 
      "months", 
      "drugs", 
      "outcomes", 
      "treatment", 
      "factors", 
      "events", 
      "mechanistic insights", 
      "randomization", 
      "study", 
      "conclusion", 
      "imaging", 
      "preliminary results", 
      "pressure", 
      "years", 
      "proportion", 
      "registration", 
      "levels", 
      "entry", 
      "test", 
      "effect", 
      "results", 
      "data", 
      "Japan", 
      "method", 
      "radionuclides", 
      "insights", 
      "design", 
      "assignment", 
      "Internet", 
      "minimization method"
    ], 
    "name": "Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results", 
    "pagination": "21-28", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010763509"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1291/hypres.31.21"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18360014"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1291/hypres.31.21", 
      "https://app.dimensions.ai/details/publication/pub.1010763509"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-05-20T07:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220519/entities/gbq_results/article/article_464.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1291/hypres.31.21"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'


 

This table displays all metadata directly associated to this object as RDF triples.

291 TRIPLES      22 PREDICATES      124 URIs      114 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1291/hypres.31.21 schema:about N0b776ab8ddd549dea55dd4ad4714fb3d
2 N1bd64da9e7bf4bf4a8a714923cc1d6a7
3 N1c187c48370d4b2e9442e755cd7fc47d
4 N1c52bf73cd00407794519363b5370f50
5 N20f29047925c4020ae1e8b2fd01e3640
6 N4ac592aae9934f76a11ba7fdb1ae3528
7 N511321e55c59464b827d5bba0e5d28ec
8 N527414be6f5549179de0d8a64828bf90
9 N60cd480e1a1847dfa09e3db1d135b285
10 N63e086297a4c43859ea448b05f3de22b
11 N6a59c74608da4b57a7ed1cabebd37f84
12 N6d70fc03d2bb4371a58497f10822b526
13 N81fc0226861b433cb25ad44057b53a7e
14 N8d0398470dfe46679de3fd9355c71d68
15 N8f461e729b914ed28a5a754980e28df5
16 N938bb49ec83d4788927702c13436de22
17 N9c2a3b03cff54054912d9db7fd7b7b47
18 Nbacf37cccbb84b9aa51449a1cbc28135
19 Nbc69dfbc52754bf2813606ab3ff508c2
20 Nc6368903c83c4de99552c577c881856c
21 Nc945773e88cd4e6f93dd3e1f1ab12634
22 Ncebdb1b9518742a28b8de24bb6ed503d
23 Ndd482f3010964ee48496a20c5676511c
24 Ne85e76c2f9b24f7495450443c18a108e
25 Nee01723d105f4fd6be66081e28d60531
26 Nff06b47d025f4b4ba0cedd8ddd2eccdc
27 anzsrc-for:11
28 anzsrc-for:1102
29 schema:author N2ba88de72ae443058b110c7056b4b060
30 schema:citation sg:pub.10.1291/hypres.28.865
31 sg:pub.10.2165/00003495-199447060-00005
32 schema:datePublished 2008-01
33 schema:datePublishedReg 2008-01-01
34 schema:description Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21−28)
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N91d118f30fa64a52820fad5a7e60b563
39 Nf2e3b4884e3d4a48b8b89c0a73950665
40 sg:journal.1313717
41 schema:keywords Internet
42 Japan
43 Japanese patients
44 amlodipine group
45 angiotensin II type 1 receptor blocker
46 antihypertensive therapy
47 assignment
48 background factors
49 baseline
50 blockers
51 blood pressure
52 calcium channel blockers
53 cardiovascular disease events
54 cardiovascular events
55 channel blockers
56 clinical outcomes
57 conclusion
58 data
59 data entry
60 design
61 diabetes
62 disease events
63 drugs
64 echocardiography
65 effect
66 entry
67 essential hypertensives
68 events
69 factors
70 group
71 hyperlipidemia
72 hypertension-related morbidity
73 hypertensives
74 imaging
75 insights
76 laboratory tests
77 levels
78 mechanistic insights
79 method
80 minimization method
81 months
82 morbidity
83 mortality
84 open-label trial
85 optimal therapy
86 outcomes
87 patients
88 preliminary results
89 pressure
90 proportion
91 proportion of patients
92 radionuclides
93 random assignment
94 randomization
95 randomized trials
96 receptor blockers
97 registration
98 results
99 study
100 target level
101 test
102 therapy
103 treatment
104 treatment effects
105 trials
106 type 1 receptor blocker
107 urine studies
108 valsartan
109 years
110 schema:name Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results
111 schema:pagination 21-28
112 schema:productId N20e711769a35441d8b4fec5a98c2e3fd
113 N2191e4f3657a4b42a4703c3ea0a727b4
114 Neb0c35e90a6441be8599dcb9fcd7a456
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010763509
116 https://doi.org/10.1291/hypres.31.21
117 schema:sdDatePublished 2022-05-20T07:24
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher Nc061331db9e642fa9f05f00751954cce
120 schema:url https://doi.org/10.1291/hypres.31.21
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N0b776ab8ddd549dea55dd4ad4714fb3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Endpoint Determination
126 rdf:type schema:DefinedTerm
127 N1b30bb102fa746cb8421dd3f16d743e2 rdf:first sg:person.0752532133.65
128 rdf:rest N258db130cd1a44aa80f5a295b41387bb
129 N1bd64da9e7bf4bf4a8a714923cc1d6a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Valine
131 rdf:type schema:DefinedTerm
132 N1c187c48370d4b2e9442e755cd7fc47d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Follow-Up Studies
134 rdf:type schema:DefinedTerm
135 N1c52bf73cd00407794519363b5370f50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Aged
137 rdf:type schema:DefinedTerm
138 N20e711769a35441d8b4fec5a98c2e3fd schema:name dimensions_id
139 schema:value pub.1010763509
140 rdf:type schema:PropertyValue
141 N20f29047925c4020ae1e8b2fd01e3640 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Female
143 rdf:type schema:DefinedTerm
144 N2191e4f3657a4b42a4703c3ea0a727b4 schema:name pubmed_id
145 schema:value 18360014
146 rdf:type schema:PropertyValue
147 N258db130cd1a44aa80f5a295b41387bb rdf:first sg:person.01312065070.00
148 rdf:rest N5aea35a7ef0c4007a516adcfaa683760
149 N2ba88de72ae443058b110c7056b4b060 rdf:first Nd3280119a31e4144a8bf9741aa3a1426
150 rdf:rest N1b30bb102fa746cb8421dd3f16d743e2
151 N2fe8d6d8373946f88280d4665e5081d8 rdf:first sg:person.01012024207.33
152 rdf:rest rdf:nil
153 N4ac592aae9934f76a11ba7fdb1ae3528 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Risk Factors
155 rdf:type schema:DefinedTerm
156 N511321e55c59464b827d5bba0e5d28ec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Informed Consent
158 rdf:type schema:DefinedTerm
159 N527414be6f5549179de0d8a64828bf90 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Valsartan
161 rdf:type schema:DefinedTerm
162 N5aea35a7ef0c4007a516adcfaa683760 rdf:first sg:person.01066760533.40
163 rdf:rest Nc6185a4e2f144d4694aacfbf2842cf0f
164 N60cd480e1a1847dfa09e3db1d135b285 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Radionuclide Imaging
166 rdf:type schema:DefinedTerm
167 N63e086297a4c43859ea448b05f3de22b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Sample Size
169 rdf:type schema:DefinedTerm
170 N6a59c74608da4b57a7ed1cabebd37f84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Male
172 rdf:type schema:DefinedTerm
173 N6d70fc03d2bb4371a58497f10822b526 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Humans
175 rdf:type schema:DefinedTerm
176 N81fc0226861b433cb25ad44057b53a7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Patient Selection
178 rdf:type schema:DefinedTerm
179 N8d0398470dfe46679de3fd9355c71d68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Prospective Studies
181 rdf:type schema:DefinedTerm
182 N8f461e729b914ed28a5a754980e28df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Ultrasonography
184 rdf:type schema:DefinedTerm
185 N91d118f30fa64a52820fad5a7e60b563 schema:volumeNumber 31
186 rdf:type schema:PublicationVolume
187 N938bb49ec83d4788927702c13436de22 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Research Design
189 rdf:type schema:DefinedTerm
190 N9c2a3b03cff54054912d9db7fd7b7b47 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Calcium Channel Blockers
192 rdf:type schema:DefinedTerm
193 Nb2cf47c4d0994997a0b735e4816061fb rdf:first sg:person.01203207133.99
194 rdf:rest Nf9bef7b1040d49de9798e474bd68fbe2
195 Nbacf37cccbb84b9aa51449a1cbc28135 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Data Interpretation, Statistical
197 rdf:type schema:DefinedTerm
198 Nbc69dfbc52754bf2813606ab3ff508c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Hypertension
200 rdf:type schema:DefinedTerm
201 Nc061331db9e642fa9f05f00751954cce schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 Nc6185a4e2f144d4694aacfbf2842cf0f rdf:first sg:person.01135073733.57
204 rdf:rest Nb2cf47c4d0994997a0b735e4816061fb
205 Nc6368903c83c4de99552c577c881856c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Radiopharmaceuticals
207 rdf:type schema:DefinedTerm
208 Nc945773e88cd4e6f93dd3e1f1ab12634 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
209 schema:name Antihypertensive Agents
210 rdf:type schema:DefinedTerm
211 Ncebdb1b9518742a28b8de24bb6ed503d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
212 schema:name Tetrazoles
213 rdf:type schema:DefinedTerm
214 Nd3280119a31e4144a8bf9741aa3a1426 schema:affiliation grid-institutes:grid.136304.3
215 schema:familyName Nakayama
216 schema:givenName Keiko
217 rdf:type schema:Person
218 Ndd482f3010964ee48496a20c5676511c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Amlodipine
220 rdf:type schema:DefinedTerm
221 Ne85e76c2f9b24f7495450443c18a108e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Angiotensin II Type 1 Receptor Blockers
223 rdf:type schema:DefinedTerm
224 Neb0c35e90a6441be8599dcb9fcd7a456 schema:name doi
225 schema:value 10.1291/hypres.31.21
226 rdf:type schema:PropertyValue
227 Nee01723d105f4fd6be66081e28d60531 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name 3-Iodobenzylguanidine
229 rdf:type schema:DefinedTerm
230 Nf2e3b4884e3d4a48b8b89c0a73950665 schema:issueNumber 1
231 rdf:type schema:PublicationIssue
232 Nf9bef7b1040d49de9798e474bd68fbe2 rdf:first sg:person.01251322333.16
233 rdf:rest N2fe8d6d8373946f88280d4665e5081d8
234 Nff06b47d025f4b4ba0cedd8ddd2eccdc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Middle Aged
236 rdf:type schema:DefinedTerm
237 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
238 schema:name Medical and Health Sciences
239 rdf:type schema:DefinedTerm
240 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
241 schema:name Cardiorespiratory Medicine and Haematology
242 rdf:type schema:DefinedTerm
243 sg:journal.1313717 schema:issn 0916-9636
244 1348-4214
245 schema:name Hypertension Research
246 schema:publisher Japanese Society of Hypertension
247 rdf:type schema:Periodical
248 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.136304.3
249 schema:familyName Komuro
250 schema:givenName Issei
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
252 rdf:type schema:Person
253 sg:person.01066760533.40 schema:affiliation grid-institutes:grid.136304.3
254 schema:familyName Shindo
255 schema:givenName Satoshi
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40
257 rdf:type schema:Person
258 sg:person.01135073733.57 schema:affiliation grid-institutes:grid.136304.3
259 schema:familyName Fujita
260 schema:givenName Miwa
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57
262 rdf:type schema:Person
263 sg:person.01203207133.99 schema:affiliation grid-institutes:grid.136304.3
264 schema:familyName Narumi
265 schema:givenName Hiroya
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99
267 rdf:type schema:Person
268 sg:person.01251322333.16 schema:affiliation grid-institutes:grid.136304.3
269 schema:familyName Mizuma
270 schema:givenName Hiroshi
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16
272 rdf:type schema:Person
273 sg:person.01312065070.00 schema:affiliation grid-institutes:grid.136304.3
274 schema:familyName Daimon
275 schema:givenName Masao
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312065070.00
277 rdf:type schema:Person
278 sg:person.0752532133.65 schema:affiliation grid-institutes:grid.136304.3
279 schema:familyName Kuwabara
280 schema:givenName Yoichi
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65
282 rdf:type schema:Person
283 sg:pub.10.1291/hypres.28.865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050983237
284 https://doi.org/10.1291/hypres.28.865
285 rdf:type schema:CreativeWork
286 sg:pub.10.2165/00003495-199447060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034980850
287 https://doi.org/10.2165/00003495-199447060-00005
288 rdf:type schema:CreativeWork
289 grid-institutes:grid.136304.3 schema:alternateName Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
290 schema:name Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
291 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...